HK56191A - Controlled release combination of carbidopa/levodopa - Google Patents

Controlled release combination of carbidopa/levodopa Download PDF

Info

Publication number
HK56191A
HK56191A HK561/91A HK56191A HK56191A HK 56191 A HK56191 A HK 56191A HK 561/91 A HK561/91 A HK 561/91A HK 56191 A HK56191 A HK 56191A HK 56191 A HK56191 A HK 56191A
Authority
HK
Hong Kong
Prior art keywords
levodopa
water soluble
soluble polymer
carbidopa
cellulose
Prior art date
Application number
HK561/91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert E. Dempski
Donald W. Nibbelink
Edward C. Scholtz
Scott A. Reines
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK56191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of HK56191A publication Critical patent/HK56191A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK561/91A 1986-06-16 1991-07-18 Controlled release combination of carbidopa/levodopa HK56191A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16

Publications (1)

Publication Number Publication Date
HK56191A true HK56191A (en) 1991-07-26

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
HK561/91A HK56191A (en) 1986-06-16 1991-07-18 Controlled release combination of carbidopa/levodopa

Country Status (17)

Country Link
EP (1) EP0253490B1 (enExample)
JP (1) JPS6354319A (enExample)
KR (1) KR950002882B1 (enExample)
AT (1) ATE58473T1 (enExample)
AU (1) AU597670B2 (enExample)
CY (1) CY1578A (enExample)
DE (1) DE3766308D1 (enExample)
DK (1) DK170514B1 (enExample)
ES (1) ES2018548B3 (enExample)
GR (1) GR3001102T3 (enExample)
HK (1) HK56191A (enExample)
IE (1) IE60508B1 (enExample)
IL (1) IL82823A (enExample)
NZ (1) NZ220599A (enExample)
PT (1) PT85049B (enExample)
SG (1) SG52191G (enExample)
ZA (1) ZA874233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2007055329A1 (ja) 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
JP2016520540A (ja) * 2013-03-28 2016-07-14 オムニアクティブ ヘルス テクノロジーズ リミテッド 脳内におけるカロテノイドの神経保護作用
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
GB2644236A (en) 2024-09-24 2026-03-25 Novumgen Ltd Orodispersible tablet composition containing carbidopa and levodopa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
DE3271647D1 (en) * 1981-07-08 1986-07-17 Key Pharma Polymeric diffusion matrix containing propranolol
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK170514B1 (da) 1995-10-09
KR880000086A (ko) 1988-03-23
ZA874233B (en) 1987-12-14
IE871559L (en) 1987-12-16
GR3001102T3 (en) 1992-05-12
NZ220599A (en) 1990-10-26
AU597670B2 (en) 1990-06-07
IL82823A (en) 1991-03-10
JPS6354319A (ja) 1988-03-08
EP0253490B1 (en) 1990-11-22
DK302587D0 (da) 1987-06-15
KR950002882B1 (ko) 1995-03-28
IL82823A0 (en) 1987-12-20
CY1578A (en) 1991-12-20
IE60508B1 (en) 1994-07-27
DK302587A (da) 1987-12-17
ATE58473T1 (de) 1990-12-15
AU7422887A (en) 1987-12-17
EP0253490A1 (en) 1988-01-20
SG52191G (en) 1991-08-23
JPH0445B2 (enExample) 1992-01-06
ES2018548B3 (es) 1991-04-16
DE3766308D1 (de) 1991-01-03
PT85049A (en) 1987-07-01
PT85049B (pt) 1990-03-08

Similar Documents

Publication Publication Date Title
EP0320051B1 (en) Controlled release combination of carbidopa/levodopa
EP0253490B1 (en) Controlled release combination of carbidopa/levodopa
US4900755A (en) Controlled release combination of carbidopa/levodopa
US4983400A (en) Controlled release combination of carbidopa/levodopa
KR930008954B1 (ko) 약용 서방 기제
US4424235A (en) Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US6419953B1 (en) Controlled release formulation of divalproex sodium
EP1140034A1 (en) Controlled release formulation of divalproex sodium
AU2010258345A1 (en) Novel pharmaceutical compositions containing pregabalin
US20050106246A1 (en) Controlled release arginine alpha-ketoglutarate
GB2105590A (en) Flotable controlled release preparations
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
EP1331972B1 (en) Pharmaceutical compositions
AU2002213900A1 (en) Pharmaceutical compositions
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2004016249A1 (en) Extended release matrix tablets
WO2005011666A1 (en) Stable sustained release oral dosage form of gabapentin
Giunchedi et al. Ketoprofen pulsatile absorption from ‘multiple unit’hydrophilic matrices
AU2003227039B9 (en) Pharmaceutical compositions
BG61200B2 (bg) Контролирано отделяща комбинация от саrвidора/lеvоdора
HUE029193T2 (en) Delayed release drug formulations of thiocolchicoside
ZA200300555B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20070608